Switch theme
Sign up to access all valuation multiples
Radiopharm Theranostics Ltd is an Australian based clinical-stage radiotherapeutics company which is targeting cancer. The company has a pipeline of around four licensed platform technologies, with diagnostic and therapeutic applications in both pre-clinical and clinical stages of development. The company is engaged in research, development and commercialization of health technologies.
2021
n/a
LTM Revenue $0.9M
LTM EBITDA -$25.9M
$12.6M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Radiopharm Theranostics has a last 12-month revenue (LTM) of $0.9M and a last 12-month EBITDA of -$25.9M.
In the most recent fiscal year, Radiopharm Theranostics achieved revenue of $0.2M and an EBITDA of -$28.3M.
Radiopharm Theranostics expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Radiopharm Theranostics valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $0.9M | XXX | $0.2M | XXX | XXX | XXX |
| Gross Profit | $0.9M | XXX | $0.2M | XXX | XXX | XXX |
| Gross Margin | 100% | XXX | 100% | XXX | XXX | XXX |
| EBITDA | -$25.9M | XXX | -$28.3M | XXX | XXX | XXX |
| EBITDA Margin | -2944% | XXX | -14732% | XXX | XXX | XXX |
| EBIT | -$28.1M | XXX | -$23.5M | XXX | XXX | XXX |
| EBIT Margin | -3197% | XXX | -12238% | XXX | XXX | XXX |
| Net Profit | -$27.5M | XXX | -$30.8M | XXX | XXX | XXX |
| Net Margin | -3130% | XXX | -16024% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Radiopharm Theranostics's stock price is AUD 0 (or $0).
Radiopharm Theranostics has current market cap of AUD 56.0M (or $36.0M), and EV of AUD 19.6M (or $12.6M).
See Radiopharm Theranostics trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $12.6M | $36.0M | XXX | XXX | XXX | XXX | $-0.02 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Radiopharm Theranostics has market cap of $36.0M and EV of $12.6M.
Radiopharm Theranostics's trades at 22.2x EV/Revenue multiple, and -0.5x EV/EBITDA.
Equity research analysts estimate Radiopharm Theranostics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Radiopharm Theranostics has a P/E ratio of -1.3x.
See valuation multiples for Radiopharm Theranostics and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $36.0M | XXX | $36.0M | XXX | XXX | XXX |
| EV (current) | $12.6M | XXX | $12.6M | XXX | XXX | XXX |
| EV/Revenue | 14.3x | XXX | 22.2x | XXX | XXX | XXX |
| EV/EBITDA | -0.5x | XXX | -0.5x | XXX | XXX | XXX |
| EV/EBIT | -0.4x | XXX | -0.5x | XXX | XXX | XXX |
| EV/Gross Profit | 14.3x | XXX | n/a | XXX | XXX | XXX |
| P/E | -1.3x | XXX | -1.2x | XXX | XXX | XXX |
| EV/FCF | -0.6x | XXX | -0.7x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialRadiopharm Theranostics's last 12 month revenue growth is -91%
Radiopharm Theranostics's revenue per employee in the last FY averaged n/a, while opex per employee averaged n/a for the same period.
Radiopharm Theranostics's rule of 40 is -12815% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Radiopharm Theranostics's rule of X is -3172% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Radiopharm Theranostics and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | -91% | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | -2944% | XXX | -4779% | XXX | XXX | XXX |
| EBITDA Growth | 2% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -12815% | XXX | -4870% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | -3172% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 5868% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 12338% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Radiopharm Theranostics acquired XXX companies to date.
Last acquisition by Radiopharm Theranostics was XXXXXXXX, XXXXX XXXXX XXXXXX . Radiopharm Theranostics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Radiopharm Theranostics founded? | Radiopharm Theranostics was founded in 2021. |
| Where is Radiopharm Theranostics headquartered? | Radiopharm Theranostics is headquartered in Australia. |
| Who is the CEO of Radiopharm Theranostics? | Radiopharm Theranostics's CEO is Mr. Riccardo Canevari. |
| Is Radiopharm Theranostics publicy listed? | Yes, Radiopharm Theranostics is a public company listed on ASX. |
| What is the stock symbol of Radiopharm Theranostics? | Radiopharm Theranostics trades under RAD ticker. |
| When did Radiopharm Theranostics go public? | Radiopharm Theranostics went public in 2021. |
| Who are competitors of Radiopharm Theranostics? | Similar companies to Radiopharm Theranostics include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Radiopharm Theranostics? | Radiopharm Theranostics's current market cap is $36.0M |
| What is the current revenue of Radiopharm Theranostics? | Radiopharm Theranostics's last 12 months revenue is $0.9M. |
| What is the current revenue growth of Radiopharm Theranostics? | Radiopharm Theranostics revenue growth (NTM/LTM) is -91%. |
| What is the current EV/Revenue multiple of Radiopharm Theranostics? | Current revenue multiple of Radiopharm Theranostics is 14.3x. |
| Is Radiopharm Theranostics profitable? | Yes, Radiopharm Theranostics is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Radiopharm Theranostics? | Radiopharm Theranostics's last 12 months EBITDA is -$25.9M. |
| What is Radiopharm Theranostics's EBITDA margin? | Radiopharm Theranostics's last 12 months EBITDA margin is -2944%. |
| What is the current EV/EBITDA multiple of Radiopharm Theranostics? | Current EBITDA multiple of Radiopharm Theranostics is -0.5x. |
| What is the current FCF of Radiopharm Theranostics? | Radiopharm Theranostics's last 12 months FCF is -$22.0M. |
| What is Radiopharm Theranostics's FCF margin? | Radiopharm Theranostics's last 12 months FCF margin is -2505%. |
| What is the current EV/FCF multiple of Radiopharm Theranostics? | Current FCF multiple of Radiopharm Theranostics is -0.6x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
